Set-up of Mass Spectrometry-based Stool Tests for Improving the Diagnosis and Management of Inflammatory Bowel Disease
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Scoring intestinal inflammation from stool protein analyses
研究概览
简要总结
Part of the success of the treatment of people living with inflammatory bowel diseases (IBD) depends on the information that the doctor can obtain from the different clinical tests. Some of these tests are invasive such as the colonoscopy but other such the fecal calprotectin test, which measures intestinal inflammation, are non-invasive and useful to evaluate the success of the treatments. Unfortunately, the results from the non-invasive tests are not always clear and need to be complete with invasive tests for the right diagnosis.
The aim of this research is to test new stool markers for assisting the gastroenterologist to diagnose inflammatory bowel conditions including Crohn's disease (CD) and ulcerative colitis (UC) and to carefully monitoring the effects of medications on remission. We are using applications based on the use of mass spectrometry for identifying the proteins that are released by the host in the stools. We have identified more than 400 proteins in total. Based on informatics, we have been able to produce lists of unique stool proteins that can rapidly inform the doctor if the person has an IBD, whether it is a CD or an UC and, more importantly for the treatment, if the IBD is active or in remission.
The purpose of this study is to validate these protein markers in a blind test, where the real diagnosis will only be revealed after the analysis of the samples.
This study will bring a new power tool to assist the gastroenterologist in the treatment of people living with IBD.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be affected with one of the two main inflammatory bowel diseases (Crohn's disease of ulcerative colitis).
- •Be invited to participate on the base of a routine follow up by their gastroenterologist.
- •Be scheduled for a calprotectin test and a colonoscopy.
- •Accept to participate and provide an extra stool sample for analysis.
排除标准
- •Having no history of inflammatory bowel disease.
- •Be affected with an history of gastrointestinal disease other than Crohn disease or ulcerative colitis.
结局指标
主要结局
Scoring intestinal inflammation from stool protein analyses
时间窗: From enrolment to the end of full data compilation, assessed up to 15 months
Assessing activity in patients affected with Crohn's disease or ulcerative colitis on a 0 to 1.0 score (0 as best score for remission to 1.0 as maximal score for activity) for evaluating intestinal inflammation by proteomics analysis of stools relative to standard clinical criteria (symptoms and results from colonoscopy, histopathology and fecal calprotectin).
次要结局
- To compare activity scores deduced from proteomics analyses to the results from colonoscopy and pathology.(From enrolment to the end of full data compilation, assessed up to 15 months)
- To compare activity scores deduced from proteomics analyses to the results from pathology.(From enrolment to the end of full data compilation, assessed up to 15 months)
- To compare activity scores deduced from proteomics analyses to the results from fecal calprotectin.(From enrolment to the end of full data compilation, assessed up to 15 months)
研究者
Jean-François Beaulieu
Professor
Université de Sherbrooke